Xu Peng, Zhang Xuecong, Wu Chi, Chen Yiwang, Lai Wenjie, Liu Liyong, Liang Jialei, Li Dan, Hong Ruimin, Zhan Senlin, Zhang Peize, Takiff Howard, Deng Guofang, Qu Jiuxin, Gao Qian
National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, China.
Department of Clinical Laboratory, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Evol Med Public Health. 2025 Jul 1;13(1):167-175. doi: 10.1093/emph/eoaf014. eCollection 2025.
Drug resistance is a major contributor to tuberculosis (TB) deaths worldwide. Understanding the dynamics of in-host evolution of (MTB) drug resistance can help to improve treatment success rates.
The microevolution of drug-resistant MTB was studied in three patients with long-standing, extensively drug-resistant TB (XDR-TB) by analyzing whole genome sequences of serial isolates collected during treatment.
We identified three patterns of MTB microevolution during long-term, ineffective treatment: (i) new drug-resistant subpopulations emerge and compete with other subpopulations during treatment; (ii) drug resistance profiles remaining stable without the emergence of new drug-resistant subpopulations; and (iii) after a drug is stopped, new drug-resistant subpopulations continue to emerge and compete with existing subpopulations.
The microevolution of drug-resistant MTB within patients on long-term ineffective treatment is complex. Subpopulations with different resistance-conferring mutations can compete with each other and with newly emerged subpopulations. Often, one subpopulation eventually dominates and achieves long-term stability. This work deepens the understanding of MTB microevolution in XDR-TB patients.
耐药性是全球结核病(TB)死亡的主要原因。了解结核分枝杆菌(MTB)耐药性的宿主内进化动态有助于提高治疗成功率。
通过分析治疗期间收集的系列分离株的全基因组序列,对三名患有长期广泛耐药结核病(XDR-TB)的患者的耐药MTB的微观进化进行了研究。
我们在长期无效治疗期间确定了MTB微观进化的三种模式:(i)治疗期间出现新的耐药亚群并与其他亚群竞争;(ii)耐药谱保持稳定,未出现新的耐药亚群;(iii)停药后,新的耐药亚群继续出现并与现有亚群竞争。
长期无效治疗患者体内耐药MTB的微观进化很复杂。具有不同耐药性赋予突变的亚群可以相互竞争,并与新出现的亚群竞争。通常,一个亚群最终占主导并实现长期稳定。这项工作加深了对XDR-TB患者MTB微观进化的理解。